Pharm osteoporosis TBL Flashcards
PH-1) Describe the steps and organ systems that participate in activating Vitamin D, and the therapeutic indications for Vitamin D. (PH-2) List the prototype anti-resorptive drugs (‘dronates’, SERM, calcitonin), describe their mechanism of action, list their clinical uses, and significant adverse effects. (PH-3) Describe the mechanism of action of teriparatide (hPTH(1-34)) , list its clinical uses, and its significant adverse effects. (PH-4) Describe the mechanism of action of cinacalcet , li (27 cards)
indications of vitamin D therapy
nutritional deficiency, chronic kidney/liver disease, hypoPTHism, nephrtotic syndrome
if kidney cannot convert vit D to active form, prescribe
calcitrol
SE of calcitrol
can overcorrect and cause hypercalcemia and hypercalciuria
form of Vitamin D converted to active in the liver
doxercalciferol
used for psoraisis
calcipotriene
tox of OD of Vit D or metaboloites
hypercalcmia, hyperphosphatemia, hypercalcuria
MOA of calcitonin
inibits bone resorption and increases renal excretion of calcium and phosphate to lower serum calcium and phosphate levels
use of calcitonin
acute reduction of calcium (pagets and hypercalcimia)
osteoporosis (stops resorption)
Raloxifine MOA
SERM - estrogen agonist in the bone while antogonozing in breast and endometrium
drug for osteoporosis in most-menopausal women
raloxifine
adverse effects of raloxafine
hot flushes and thromboembolism
common name of Bisphosphonates
“dronates”
treat hypercalcimia from Pagets of malignancies
bisphosphonates
parental bisphosphanates
pamidronate, zoledronic acid, etidronate (PEZ)
increases bone density and reduces fractures
bisphosphonates
chronic therapy to prevent and treat osteoporisis
bisphosphonates
annual infusion bisphosphonates
zoledronate
daily bisphosphonates
alendronate, risedronate, ibandronate
can cause gastric and esophogeal irritation
bisphosphonates
can cause osteonecrosis of jaw
bisphosphonates
hPTH(1-34) use
parental treatment for osteonecrosis
MOA of hPTH(1-34)
recombinant PTH that increases bone formation
adverse effects of hPTH(1-34)
hypercalcmia, hypercaliuria
MOA of cinacalcet
lowers PTH by activating calcium recetor in PTH gland (dummy calcium)
